糖腎康飲治療早期糖尿病腎病的臨床療效觀察及對(duì)VEGF的影響
發(fā)布時(shí)間：2018-08-02 13:00
【摘要】：目的:通過(guò)觀察糖腎康飲治療早期糖尿病腎病的療效及對(duì)血清VEGF表達(dá)水平的影響,客觀評(píng)價(jià)糖腎康飲的臨床療效,并探討其可能作用機(jī)制。方法:選取在2016年1月至2017年1月期間于黑龍江中醫(yī)藥大學(xué)附屬第一醫(yī)院內(nèi)分泌門(mén)診診斷為早期糖尿病腎病,中醫(yī)辨證為氣陰兩虛兼瘀證的患者80例,隨機(jī)分為治療組和對(duì)照組各40例。全部患者予基礎(chǔ)治療,包括糖尿病教育、飲食調(diào)攝、運(yùn)動(dòng)療法、皮下注射胰島素控制血糖、厄貝沙坦75mg日一次口服,治療組在此基礎(chǔ)上加服糖腎康飲。本次臨床觀察持續(xù)8周,觀察治療前后患者UAER、血清VEGF、血脂及中醫(yī)證候積分的變化情況。結(jié)果:1.經(jīng)8周治療后,治療組中醫(yī)證侯積分改善情況顯著優(yōu)于對(duì)照組(P0.05),治療組和對(duì)照組中醫(yī)證候總有效率分別為82.0%和36.8%,治療組中醫(yī)證候療效顯著優(yōu)于對(duì)照組(P0.05)。2.經(jīng)8周治療后,治療組總有效率87.2%,對(duì)照組總有效率55.3%,治療組臨床效果顯著優(yōu)于對(duì)照組(P0.05)。3.經(jīng)8周治療后,兩組血脂相關(guān)指標(biāo)均較治療前改善(P0.05),組間差值比較顯示治療組改善TC、TG、LDL-C、HDL-C程度顯著優(yōu)于對(duì)照組(P0.05)。4.經(jīng)8周治療后,兩組UAER均較治療前顯著降低(P0.05);組間差值比較顯示治療組降低UAER顯著優(yōu)于對(duì)照組(P0.05)。5.經(jīng)8周治療后,兩組血清VEGF均顯著減低(P0.05),組間差值比較顯示治療組降低血清VEGF顯著優(yōu)于對(duì)照組(P0.05)。結(jié)論:1.糖腎康飲可有效降低早期糖尿病腎病患者UAER水平,減輕腎損傷程度;2.糖腎康飲可改善早期糖尿病腎病氣陰兩虛兼瘀證患者中醫(yī)臨床癥狀;3.糖腎康飲可降低患者TC、TG、LDL-C水平,具有升高患者HDL-C的作用,可改善脂代謝紊亂;4.糖腎康飲可能通過(guò)減少患者血清VEGF的表達(dá)起到延緩DN進(jìn)展的作用。
[Abstract]:Objective: to evaluate the clinical efficacy of Tangshenkang decoction in the treatment of early diabetic nephropathy and to explore its possible mechanism by observing the effect of Tangshenkang decoction on the expression of serum VEGF. Methods: from January 2016 to January 2017, 80 patients were diagnosed as early diabetic nephropathy in the endocrine clinic of the first affiliated Hospital of Heilongjiang University of traditional Chinese Medicine. They were randomly divided into treatment group (n = 40) and control group (n = 40). All patients were treated with basic treatment, including diabetes education, diet adjustment, exercise therapy, subcutaneous injection of insulin to control blood glucose, irbesartan 75mg once a day, the treatment group on the basis of taking Tangshenkang decoction. The clinical observation lasted 8 weeks. The changes of UAER, serum VEGF, blood lipid and TCM syndromes were observed before and after treatment. The result is 1: 1. After 8 weeks treatment, the improvement of TCM syndrome score in treatment group was significantly better than that in control group (P0.05). The total effective rate of TCM syndrome in treatment group and control group were 82.0% and 36.8%, respectively. The curative effect of TCM syndrome in treatment group was significantly better than that in control group (P0.05). 2. After 8 weeks of treatment, the total effective rate of the treatment group was 87.2 and the total effective rate of the control group was 55.3. The clinical effect of the treatment group was significantly better than that of the control group (P0.05). 3. After 8 weeks of treatment, the serum lipids in both groups were improved compared with those before treatment (P0.05), and the difference between the two groups showed that the degree of HDL-C in the treatment group was significantly better than that in the control group (P0.05). 4. After 8 weeks of treatment, the UAER in both groups was significantly lower than that before treatment (P0.05), and the difference between groups showed that the decrease of UAER in the treatment group was significantly better than that in the control group (P0.05). After 8 weeks of treatment, the serum VEGF in both groups was significantly decreased (P0.05), and the difference between the two groups showed that the decrease of serum VEGF in the treatment group was significantly better than that in the control group (P0.05). Conclusion 1. Tangshenkang decoction can effectively reduce the level of UAER in patients with early diabetic nephropathy and alleviate the severity of renal injury. Tangshenkang decoction can improve the clinical symptoms of early diabetic nephropathy patients with deficiency of qi and yin and blood stasis. Tangshenkang decoction can reduce the LDL-C level of TCU TGG, increase the level of HDL-C in patients, and improve lipid metabolism disorder 4. 5%. Tangshenkang decoction may delay the progression of DN by reducing the expression of serum VEGF.
【學(xué)位授予單位】：黑龍江中醫(yī)藥大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R259
本文編號(hào)：2159516
[Abstract]:Objective: to evaluate the clinical efficacy of Tangshenkang decoction in the treatment of early diabetic nephropathy and to explore its possible mechanism by observing the effect of Tangshenkang decoction on the expression of serum VEGF. Methods: from January 2016 to January 2017, 80 patients were diagnosed as early diabetic nephropathy in the endocrine clinic of the first affiliated Hospital of Heilongjiang University of traditional Chinese Medicine. They were randomly divided into treatment group (n = 40) and control group (n = 40). All patients were treated with basic treatment, including diabetes education, diet adjustment, exercise therapy, subcutaneous injection of insulin to control blood glucose, irbesartan 75mg once a day, the treatment group on the basis of taking Tangshenkang decoction. The clinical observation lasted 8 weeks. The changes of UAER, serum VEGF, blood lipid and TCM syndromes were observed before and after treatment. The result is 1: 1. After 8 weeks treatment, the improvement of TCM syndrome score in treatment group was significantly better than that in control group (P0.05). The total effective rate of TCM syndrome in treatment group and control group were 82.0% and 36.8%, respectively. The curative effect of TCM syndrome in treatment group was significantly better than that in control group (P0.05). 2. After 8 weeks of treatment, the total effective rate of the treatment group was 87.2 and the total effective rate of the control group was 55.3. The clinical effect of the treatment group was significantly better than that of the control group (P0.05). 3. After 8 weeks of treatment, the serum lipids in both groups were improved compared with those before treatment (P0.05), and the difference between the two groups showed that the degree of HDL-C in the treatment group was significantly better than that in the control group (P0.05). 4. After 8 weeks of treatment, the UAER in both groups was significantly lower than that before treatment (P0.05), and the difference between groups showed that the decrease of UAER in the treatment group was significantly better than that in the control group (P0.05). After 8 weeks of treatment, the serum VEGF in both groups was significantly decreased (P0.05), and the difference between the two groups showed that the decrease of serum VEGF in the treatment group was significantly better than that in the control group (P0.05). Conclusion 1. Tangshenkang decoction can effectively reduce the level of UAER in patients with early diabetic nephropathy and alleviate the severity of renal injury. Tangshenkang decoction can improve the clinical symptoms of early diabetic nephropathy patients with deficiency of qi and yin and blood stasis. Tangshenkang decoction can reduce the LDL-C level of TCU TGG, increase the level of HDL-C in patients, and improve lipid metabolism disorder 4. 5%. Tangshenkang decoction may delay the progression of DN by reducing the expression of serum VEGF.
【學(xué)位授予單位】：黑龍江中醫(yī)藥大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R259
【參考文獻(xiàn)】
相關(guān)期刊論文 前10條
1 謝燈飄;阮詩(shī)瑋;;阮詩(shī)瑋教授治療肝腎陰虛型糖尿病腎病臨床經(jīng)驗(yàn)[J];亞太傳統(tǒng)醫(yī)藥;2017年04期
2 薛青;;益腎泄?jié)岱街委熖悄虿∧I病氣陰兩虛、腎絡(luò)瘀阻證臨床研究[J];中醫(yī)學(xué)報(bào);2017年02期
3 王藝;彭國(guó)慶;江新泉;宋文剛;張秋玲;王慶寶;李文;;黃精多糖對(duì)糖尿病大鼠模型的保護(hù)機(jī)制研究[J];中醫(yī)藥導(dǎo)報(bào);2017年02期
4 孟加寧;姚源璋;;姚源璋教授治療糖尿病腎病經(jīng)驗(yàn)介紹[J];中國(guó)中西醫(yī)結(jié)合腎病雜志;2017年01期
5 王東;李陽(yáng)欣;李敬林;;從脾腎虧虛論治糖尿病腎病[J];遼寧中醫(yī)雜志;2017年01期
6 王鴻;馬志紅;張美蓮;田俊萍;;2型糖尿病患者血尿酸與腎臟損害的相關(guān)性分析[J];山西醫(yī)藥雜志;2017年01期
7 胡鋼;;李果烈治療早期糖尿病腎病經(jīng)驗(yàn)[J];河南中醫(yī);2017年01期
8 張舒;查敏;嚴(yán)倩華;葉麗芳;黃莉吉;余江毅;;芪葵方對(duì)糖尿病腎病患者血糖、血脂、腎功能以及尿足細(xì)胞相關(guān)蛋白的影響研究[J];中藥材;2016年10期
9 劉洪;熊維建;鄭新;;國(guó)醫(yī)大師鄭新論治糖尿病腎病的學(xué)術(shù)思想和臨證經(jīng)驗(yàn)[J];中華中醫(yī)藥雜志;2016年11期
10 殷芳;楊宇峰;石巖;;糖尿病腎病中醫(yī)病因病機(jī)理論框架結(jié)構(gòu)研究[J];遼寧中醫(yī)藥大學(xué)學(xué)報(bào);2016年11期
，本文編號(hào)：2159516
本文鏈接：http://sikaile.net/zhongyixuelunwen/2159516.html
最近更新
教材專著
